Our Team


Dr. Jeremy Blitzer

jblitzer@potrerohilltherapeutics.com

Dr. Blitzer is a co-founder and Managing Director of Potrero Hill Therapeutics. Jeremy was also Partner & VP Product Development at Synergenics, where he had both strategic and operational roles in Synergenics’s biopharmaceutical division, including evaluation of new drug discovery and development opportunities, formation of new companies, and day-to-day responsibility for nearly all aspects of advancing new drug candidates from inception through IND and clinical proof-of-concept.  In particular, he had a key role in the discovery and development activities of Pathologica and BioEnergenix, which are both currently acquisition candidates with an open IND in the case of Pathologica. Synergenics, which owns and operates a portfolio of biotechnology, small-molecule therapeutics, diagnostic, and healthcare IT companies in the US and Europe, was founded in 2004 by William J. Rutter, a founder of Chiron Corporation and former head of UCSF's biochemistry and biophysics department. Prior to joining Synergenics, Jeremy obtained M.D. and Ph.D. degrees from Stanford University School of Medicine, as well as a bachelor’s degree in Chemistry from Duke University.


Stephen Halasz 

​stevehalasz@potrerohilltherapeutics.com

Mr. Halasz is a co-founder and Managing Director of Potrero Hill Therapeutics, and has also been a partner in Synergenics since 2006, where Mr. Halasz has been responsible for negotiating and structuring all significant transactions, including mergers and acquisitions, equity and debt financings, university spinouts, research collaborations, partnerships and pharma collaborations, licensing, and supply and distribution relationships, as well as being responsible for regulatory matters, resolution of disputes and for strategy for and management of an international portfolio of several hundred patents. Prior to joining Synergenics, Mr. Halasz was in private law practice where he handled a wide variety of transactions including mergers and acquisitions, corporate finance, leveraged buy-outs, securities offerings, licensing transactions, and international commercial transactions. He has experience in many industries besides the life sciences, including telecommunications, cable television, computer software and hardware, and manufacturing. Mr. Halasz is a graduate of Yale College and the Yale Law School.